Evidence, not personal-use guidance
This page explains research terminology and documentation. It does not provide medical advice, dosing, injection, administration or a recommendation to obtain or use any substance.
What is Thymosin alpha-1?
Thymosin alpha-1 is a 28-amino-acid peptide studied in immune signalling and in clinical contexts across several jurisdictions.
Search results often combine research papers, supplier descriptions and personal claims. Those sources answer different questions. A paper can describe a mechanism or study outcome; only a batch-specific analytical record can describe the tested sample.
Identity and naming
It must be distinguished from thymosin beta-4 and products labelled TB-500. They are unrelated sequences despite sharing the thymosin name.
Useful records state the exact material, expected molecular characteristics, batch code, sample identifier and form. See peptide sequence and molecular weight for why a familiar name is not enough.
What the research base shows
The literature includes molecular, animal and human clinical research, with regulatory status varying by country and indication. Evidence should be evaluated for the exact condition, formulation and study design.
Evidence should be sorted by level: biochemical or cell studies, animal models, observational human data, controlled trials and regulatory evidence. A result at one level should not be silently rewritten as a conclusion at another.
Analytical and COA questions
Confirm the 28-residue identity, mass and chromatographic profile. Shared family naming makes accurate label-to-report matching especially important.
- Does the report name this exact molecular form?
- Does the sample or batch code match the container?
- Are identity, peak-area purity and quantitative content reported separately?
- Can the laboratory and report number be independently traced?
Use the field-by-field COA guide before relying on a headline percentage.
What this page cannot establish
It cannot establish that any commercial material is genuine, sterile, safe, legally supplied or suitable for a particular purpose. Regulatory status and authorised uses can change and vary by country; consult the MHRA Products registry and other relevant official sources.
Frequently asked questions
Is thymosin alpha-1 the same as TB-500?
No. Thymosin alpha-1 and thymosin beta-4 are different peptides.
Is it approved everywhere?
Regulatory status varies by jurisdiction and must be checked with the relevant authority.
Related external reading:
- testing terminology guideexternal · supplier educational page
External links are editorial references, not endorsements.
Research sources
- PubMed literature search: Thymosin alpha-1.
- ClinicalTrials.gov search: Thymosin alpha-1.
- IUPAC peptide terminology.
- ICH Q2(R2): analytical procedure validation.
Search links are provided because the literature and regulatory status can change. Sources were checked on 19 September 2026.